Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GW685698X in Seasonal Allergic Rhinitis
NCT00225823Phase 3Completed
- Sponsor
- GSK
- Start
- May 2005
- Primary completion
- Aug 2005
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing GW685698X with Placebo (2 arms). Primary endpoint: Reflective Total Nasal Symptom Score at 2 weeks. Started May 2005; status: completed.
02
Drugs
fluticasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00225823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225823.